Literature DB >> 6414324

Results of surgery alone and surgery combined with postoperative radiotherapy in the treatment of cancer of the parotid gland.

G L Jackson, M A Luna, R M Byers.   

Abstract

Seventy-seven patients with primary malignant parotid tumors were studied and the various factors relative to their disease, as well as their treatment, were analyzed. Because of the retrospective nature of this study, no attempt was made to compare surgery alone with surgery and postoperative radiation, but it was interesting to reflect on the relative and absolute indications for the use of combined treatment versus surgery alone. The above-clavicle control in this group of patients was excellent, and the relatively low incidence of distant metastases reflect that optimal local control was closely correlated with survival. Sacrifice of the facial nerve should not be routinely based on the histologic characteristics of the tumor but rather on the findings at the time of surgery. Elective regional node dissection was indicated as a staging adjuvant and to provide extra exposure and soft tissue margins of excision in large tumors without producing any significant additional morbidity.

Entities:  

Mesh:

Year:  1983        PMID: 6414324     DOI: 10.1016/0002-9610(83)90239-8

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  3 in total

1.  Management of malignant parotid tumors.

Authors:  Nikolaos Papadogeorgakis; Lampros Goutzanis; Vassilis Petsinis; Constantinos Alexandridis
Journal:  Oral Maxillofac Surg       Date:  2011-01-05

Review 2.  Role of fine needle aspiration cytology in the management of the discrete parotid lump.

Authors:  M McGurk; K Hussain
Journal:  Ann R Coll Surg Engl       Date:  1997-05       Impact factor: 1.891

3.  Parotid cancer treatment with surgery followed by radiotherapy in Oxford over 15 years.

Authors:  Ketan Shah; Faisal Javed; Chris Alcock; Ketan A Shah; Pieter Pretorius; Chris A Milford
Journal:  Ann R Coll Surg Engl       Date:  2011-04       Impact factor: 1.891

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.